Unknown

Dataset Information

0

Bispecific antibody releasing-mesenchymal stromal cell machinery for retargeting T cells towards acute myeloid leukemia blasts.


ABSTRACT: Bispecific antibodies (bsAbs) engaging T cells are emerging as a promising immunotherapeutic tool for the treatment of hematologic malignancies. Because their low molecular mass, bsAbs have short half-lives. To achieve clinical responses, they have to be infused into patients continously, for a long period of time. As a valid alternative we examined the use of mesenchymal stromal cells (MSCs) as autonomous cellular machines for the constant production of a recently described, fully humanized anti-CD33-anti-CD3 bsAb, which is capable of redirecting human T cells against CD33-expressing leukemic cells. The immortalized human MSC line SCP-1 was genetically modified into expressing bsAb at sufficient amounts to redirect T cells efficiently against CD33 presenting target cells, both in vitro and in an immunodeficient mouse model. Moreover, T cells of patients suffering from acute myeloid leukemia (AML) in blast crisis eliminated autologous leukemic cells in the presence of the bsAb secreting MSCs over time. The immune response against AML cells could be enhanced further by providing T cells an additional co-stimulus via the CD137-CD137 ligand axis through CD137L expression on MSCs. This study demonstrates that MSCs have the potential to be used as cellular production machines for bsAb-based tumor immunotherapy in the future.

SUBMITTER: Aliperta R 

PROVIDER: S-EPMC4648523 | biostudies-literature | 2015 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Bispecific antibody releasing-mesenchymal stromal cell machinery for retargeting T cells towards acute myeloid leukemia blasts.

Aliperta R R   Cartellieri M M   Feldmann A A   Arndt C C   Koristka S S   Michalk I I   von Bonin M M   Ehninger A A   Bachmann J J   Ehninger G G   Bornhäuser M M   Bachmann M P MP  

Blood cancer journal 20150918


Bispecific antibodies (bsAbs) engaging T cells are emerging as a promising immunotherapeutic tool for the treatment of hematologic malignancies. Because their low molecular mass, bsAbs have short half-lives. To achieve clinical responses, they have to be infused into patients continously, for a long period of time. As a valid alternative we examined the use of mesenchymal stromal cells (MSCs) as autonomous cellular machines for the constant production of a recently described, fully humanized ant  ...[more]

Similar Datasets

| S-EPMC5386336 | biostudies-literature
| S-EPMC3684350 | biostudies-literature
| S-EPMC8665988 | biostudies-literature
| S-EPMC9165478 | biostudies-literature
| S-EPMC6900505 | biostudies-literature
| S-EPMC6295344 | biostudies-literature
| S-EPMC9153005 | biostudies-literature
| S-EPMC8215192 | biostudies-literature
| S-EPMC11305399 | biostudies-literature
| S-EPMC4450324 | biostudies-literature